Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma

QR Code

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma

The mRNA expression of the dipeptidyl peptidase 4 (DPP4) gene family is highly upregulated in human hepatocellular carcinoma (HCC) and is associated with poor survival in HCC patients. Compounds that inhibit the DPP4 enzyme family, such as talabostat and ARI-4175, can mediate tumour regression by im...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	James M. Henderson, Michelle S. W. Xiang, Jiali Carrie Huang, Stefanie Wetzel, Linxuan Jiang, Jack H. Lai, Wengen Wu, James G. Kench, William W. Bachovchin, Ben Roediger, Geoffrey W. McCaughan, Hui Emma Zhang, Mark D. Gorrell
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	ARI-4175 pan-DPP inhibitor DPP4 HCC caspase-1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/04651d7d2ee047aa86a1c58c3e6fff83
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
par: Taras S. Panevin, et autres
Publié: (2020)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
par: Lyudmila Viktorovna Nedosugova, et autres
Publié: (2014)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
par: Taehwan Park, et autres
Publié: (2021)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
par: Woodman OL, et autres
Publié: (2019)

Sequential alcalase and flavourzyme treatment for preparation of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP)-IV inhibitory peptides from oat protein
par: Lourdes Ramírez Fuentes, et autres
Publié: (2021)

Linagliptin use in older individuals with type 2 diabetes
par: Pratley RE
Publié: (2014)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
par: Editorial team Diabetes Mellitus
Publié: (2012)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
par: Elena Valer'evna Biryukova
Publié: (2014)

New prospects in the treatment of diabetes mellitus
par: Minara Shamkhalovna Shamkhalova, et autres
Publié: (2012)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
par: Alexander Sergeevich Ametov, et autres
Publié: (2010)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
par: Ghosh S, et autres
Publié: (2016)

Vildagliptin: the first innovative DDP-4 inhibitor
par: Edvin Villkhauer
Publié: (2010)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
par: Karyekar CS, et autres
Publié: (2013)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
par: Shen L, et autres
Publié: (2021)

Saxagliptin for type 2 diabetes
par: Chacra
Publié: (2010)

Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
par: Gagik R. Galstyan, et autres
Publié: (2016)

The new drug saxagliptin is now registrated in Russia
par: Editorial team Diabetes Mellitus
Publié: (2010)

Control of type 2 diabetes mellitus: problems and prospects for their solution
par: Tatiana Ivanovna Romantsova, et autres
Publié: (2009)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
par: Marina Vladimirovna Shestakova
Publié: (2010)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
par: Anna A. Mosikian, et autres
Publié: (2018)

Russian Association of Endocrinologists reports commencement of Trajenta clinical use
par: Editorial team Diabetes Mellitus
Publié: (2012)

Teneligliptin in management of type 2 diabetes mellitus
par: Sharma SK, et autres
Publié: (2016)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
par: Yu H, et autres
Publié: (2017)

Expert committee on introduction of incretin-based therapy in Russia: advance and failure
par: Editorial team Diabetes Mellitus
Publié: (2012)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
par: Marina Vladimirovna Shestakova
Publié: (2011)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
par: Cheng F, et autres
Publié: (2019)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
par: Osonoi T, et autres
Publié: (2020)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
par: Yury Ivanovich Suntsov
Publié: (2012)

DPP4 Regulates DHCR24-Mediated Cholesterol Biosynthesis to Promote Methotrexate Resistance in Gestational Trophoblastic Neoplastic Cells
par: Weijie Yuan, et autres
Publié: (2021)

Dysregulation of DPP4-CXCL12 Balance by TGF-β1/SMAD Pathway Promotes CXCR4+ Inflammatory Cell Infiltration in Keloid Scars
par: Chen Z, et autres
Publié: (2021)

Vildagliptin and its role in the treatment of diabetes mellitus
par: Yury Shavkatovich Khalimov
Publié: (2010)

Prediction of Non-canonical Routes for SARS-CoV-2 Infection in Human Placenta Cells
par: Flávia Bessi Constantino, et autres
Publié: (2021)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
par: Alina Babenko, et autres
Publié: (2014)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
par: Teragawa H, et autres
Publié: (2020)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
par: Gallwitz B
Publié: (2010)

In vivo and in vitro Evaluation of Cytokine Expression Profiles During Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection
par: Mubarak A, et autres
Publié: (2021)

The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia
par: Juraj Secnik, et autres
Publié: (2021)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
par: De Nigris V, et autres
Publié: (2021)

Synergistic antidiabetic activity of Taraxacum officinale (L.) Weber ex F.H.Wigg and Momordica charantia L. polyherbal combination
par: Nithiyaa Perumal, et autres
Publié: (2022)